Suspension aerosol formulations of pharmaceutical products

Abstract

Pharmaceutical preparations for producing powder aerosols using propellant gases which use TG 227, and possibly also TG 11, TG 12, TGH 114, propane, butane, pentane or DME.

1 . Propellent gases characterised in that they contain TG 227, in admixture with one or more propellent gases from the group comprising TG 11, TG 12, TG 114, propane, butane, pentane and DME. 
   
   
       2 . Propellent gases according to  claim 1 , characterised in that they additionally contain at least one surface-active substance. 
   
   
       3 . Propellent gases according to  claim 2 , characterised in that the surface-active substance is a prospholipid, a sorbitan ester with a higher saturated or unsaturated fatty acid or a polyethoxysorbitan ester of a higher, preferably unsaturated fatty acid. 
   
   
       4 . Propellent gases according to  claim 2 , characterised in that the surface-active substance is a lecithin, a polyethoxyethylenesorbitan oleate or sorbitan trioleate. 
   
   
       5 . Pharmaceutical preparations for producing powder aerosols based on propellent gases according to  claim 1  characterised in that they contain as active substance a betamimetic, an anticholinergic, a steroid, an antiallergic or a PAF-antagonist or a combination of such compounds. 
   
   
       6 . Pharmaceutical preparations according to  claim 5 , characterised in that the betamimetic used is selected from the group consisting of Bambuterol, Bitolterol, Carbuterol, Clenbuterol, Fenoterol, Hexoprenalin, Ibuterol, Pirbuterol, Procaterol, Reproterol, Salbutamol, Salmeterol, Sulfonterol, Terbutalin, Tulobuterol, 1-(2-fluoro-4-hydroxyphenyl)-2-[4-(1-benzimidazolyl)-2-methyl-2-butylamino]ethanol, erythro-5′-hydroxy-8′-(1-hydroxy-2-isopropylaminobutyl)-2H-1,4-benzoxazin-3-(4H)-one, 1-(4-amino-3-chloro-5-trifluoromethylphenyl)-2-tert.-butylamino)ethanol and 1-(4-ethoxycarbonylamino-3-cyano-5-fluorophenyl)-2-(tert.-butylamino)ethanol
 the anticholinergic used is selected from the group consisting of Ipratropium bromide, Oxitropium bromide, Trospium chloride, Benzilic acid-N-β-fluoroethylnortropine ester, and methobromide;   the steroid used is selected from the group consisting Budesonide, Beclomethasone or the 17,21-dipropionate thereof, Dexamethason-21-isonicotinate, and Flunisolide;   the antiallergic agent is selected from the group consisting of Disodium cromoglycate and Nedocromil; and   the PAF-antagonist is selected from the group consisting of 4-(2-Chlorophenyl)-9-methyl-2-[3-(4-morpholinyl)-3-propanon-1-yl]-6H-thieno[3.2-f][1.2.4]triazolo[4.3-a][1.4]diazepine, 3-(Morpholin-4-yl-carbonyl)-5-(2-chlorphenyl)-10-methyl-7H-cyclopental[4.5]thieno-[3.2-f][1.2.4]triazolo[4.3-a][1.4]diazepine, and 3-(Di-n-propylamincarbonyl)-5-(2-chlorophenyl)-10-methyl-7H-cyclopental[4.5]thieno-[3.2-f][2.4]triazolo[4.3-a][1.4]diazepine.   
   
   
       7 .- 10 . (canceled) 
   
   
       11 . Process for preparing pharmaceutical preparations according to  claim 5 , characterised in that pharmaceutically active substances micronised by conventional methods are suspended in a liquefied propellent gas mixture optionally with the addition of surface-active substances.